Archive · 29 Jul 2026
ICMR's Cervical Cancer Pill Shows Promise
The ICMR has developed a new pill called SHetA2 that can stop the HPV virus from causing cervical cancer.
This pill works by targeting the proteins that the virus uses to cause cancer.
The pill is different from the HPV vaccine, which prevents infection.
Cervical cancer is a big problem in India, and this new pill could be a game-changer.
The pill is cost-effective and easy to make, which means it could be accessible to many people.
The ICMR is conducting larger human trials to see how well the pill works.
If successful, this could be a major breakthrough in the fight against cervical cancer.
ICMR's SHetA2 pill targets HPV's cancer-causing proteins.
SHetA2 is cost-effective and easy to manufacture.
Cervical cancer is the second most common cancer among women in India.
HPV vaccine prevents infection but requires multiple doses.
SHetA2 pill is undergoing larger human trials for effectiveness.
- Who
- ICMR National Institute of Cancer Prevention and Research (ICMR-NICPR)
- What
- Development of SHetA2 pill to stop HPV from turning cancerous.
- When
- July 29, 2026
- Where
- India
- Why
- To provide a new treatment option for cervical cancer.
Cervical Cancer Prevention
HPV Vaccination
Effectiveness
Cervical Cancer Prevention
SHetA2 pill targets cancer-causing proteins and stops HPV from turning cancerous.
HPV Vaccination
HPV vaccine prevents infection and is highly effective in reducing cervical cancer risk.
Accessibility
Cervical Cancer Prevention
SHetA2 pill is cost-effective and easy to manufacture.
HPV Vaccination
HPV vaccine requires multiple doses and may be less accessible in some regions.
- SHetA2
- A small molecule therapy designed to stop HPV from causing cancer.
- HPV
- Human papillomavirus, a virus that can cause cervical cancer.
- Cervical Cancer
- The second most common cancer among women in India.
- ICMR
- Indian Council of Medical Research.
- HPV Vaccine
- A vaccine that prevents HPV infection and reduces cervical cancer risk.